NANETS in collaboration with the Society of Nuclear Medicine and Molecular Imaging presents:
PRRT: Background, Published Results, Patient Selection Details, Sequencing of Therapy, and Future Directions

Members can view the recording of this webinar - and obtain credits until July 2021. Please login here

Lisa Bodei, MD, Memorial Sloan Kettering Cancer Center
Jonathan Strosberg, MD, Moffitt Cancer Center

Learning Objectives:

  • Understand the regulatory considerations for the administration of 177Lu-DOTATATE
  • Appreciate the logistical considerations and space planning for treatment
  • Understand the adjunctive medication options and their appropriate utilization
  • Understand where 177Lutetium-dotatate might fit within the neuroendocrine tumor treatment landscape
  • Understand impact of PRRT on key endpoints including progression-free survival and health-related quality of life
  • Identify potential risks of 177Lutetium-dotatate, including long-term myelotoxicity

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The CMEsolutions designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™, MOC and nursing continued education credits